Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block shows promise for Alzheimer's symptoms in small trial

NCT ID NCT07351773

Symptom relief Sponsor: Taizhou Second People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a procedure called a stellate ganglion block (SGB), given with standard medication, could improve thinking and memory in people with Alzheimer's disease. Forty participants were randomly assigned to receive either SGB plus standard drugs or standard drugs alone. The main goal was to see if the SGB group had better cognitive scores one month after treatment, and to check for any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jan 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 55 to 85 years. 2. Diagnosis of Alzheimer's disease (AD) based on the 2011 NIA-AA criteria. 3. Mild to moderate cognitive impairment assessed by the Mini-Mental State Examination (MMSE). 4. Ability to understand study procedures and provide written informed consent by the participant or a legally authorized representative. 5. Ability to complete scheduled follow-up assessments. Exclusion Criteria: 1. Known allergy to lidocaine, coagulation disorders, or other contraindications to stellate ganglion block (SGB). 2. Severe cardiac, hepatic, or renal disease that could compromise safety. 3. Cranial surgery or major head trauma within the past 6 months. 4. Participation in other interventional trials that could affect study outcomes. 5. Cognitive impairment primarily due to other neurodegenerative diseases or psychiatric disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease(AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease anxiety disorder cognitive disorder Cognitive Dysfunction Depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease(AD) Cognitive dysfunction

Contacts and locations

Locations

  • Taizhou Second People's Hospital

    Taizhou, Zhejiang, 317200, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.